Kirsten Vrenken, PhD candidate in the group of Frank van Leeuwen, theme Cancer development and immune defense, has received the Tom Voûte Young Investigator Award 2018. This price is awarded each year by Kika (kinderen kankervrij) for excellent research in the area of pediatric oncology.
Kirsten presented her research about the role of EMT transcription factor Snail2 in neuroblastoma.Although Kirsten recently switched to the Van Leeuwen group at the Princess Máxima Center in Utrecht to complete her research, she has done most of the work for her research at the Radboudumc, on the basis of a RIMLS personal grant she aquired in 2014.
Tom Voûte Young Investigator Award 2018: link
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
T cell immunity is directed by tetraspanin CD53
5 July 2022 T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood. read moreA single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta
21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read moreDutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs
14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read moreEuropean grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant
26 April 2022The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.
read more